Abstract
Background: The first monoclonal antibody biosinnilar to be used in clinical practice is the tumour necrosis factor-alpha inhibitor Rennsima (R) (CT-P......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
